Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences, Inc. (Nasdaq: CRBU) is a clinical-stage CRISPR genome-editing biopharmaceutical company whose news flow is driven by developments in its allogeneic CAR-T cell therapy programs and related corporate updates. The company focuses on vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma.
News about Caribou frequently covers clinical trial milestones, including data readouts from the ANTLER phase 1 trial of vispa-cel and the CaMMouflage phase 1 trial of CB-011. Company press releases have highlighted efficacy and durability data in defined patient cohorts, safety profiles that support outpatient administration for vispa-cel, and dose selection and expansion plans for CB-011 in heavily pretreated multiple myeloma populations.
Investors and followers of CRBU can also expect updates on regulatory interactions and designations, such as RMAT, Fast Track, and Orphan Drug status, as well as communications about planned pivotal trial designs. In addition, Caribou issues quarterly financial results and business updates via press releases and Form 8-K filings, which provide context on its operating runway, research and development spending, and strategic pipeline prioritization.
Another recurring category of news involves conference participation and webcasts, where Caribou’s management and clinical investigators present data at major hematology and oncology meetings and biopharma investor conferences. These events often coincide with new clinical data disclosures or discussions of next steps in trial development.
This news page aggregates such announcements so readers can follow Caribou’s progress in CRISPR-based genome editing, allogeneic CAR-T development, and its lead programs in lymphoma and multiple myeloma. For those tracking CRBU, regular review of this feed helps monitor key clinical, regulatory, and corporate milestones.
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in two upcoming investor conferences. Rachel Haurwitz, PhD, the company's president and CEO, will join a panel on cell therapies in autoimmune disorders at Citi's 2024 Global Healthcare Conference in Miami on December 3 at 2:30 PM EST. She will also participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables on December 4 at 10:25 AM EST. Webcasts of both events will be available on Caribou's website for 30 days following the presentations.
Caribou Biosciences reported Q3 2024 financial results, highlighting progress across four clinical-stage programs. The company reported a net loss of $34.7 million and revenue of $2.0 million. Cash position stands at $281.0 million, expected to fund operations into H2 2026. Key developments include advancing CB-010 for LBCL and lupus, CB-011 for multiple myeloma with encouraging efficacy observations, and CB-012 for AML. The company received Fast Track designations for CB-010 and CB-012, and plans multiple clinical data reports throughout 2025.
Caribou Biosciences, Inc. (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced that an abstract has been accepted for a poster presentation at the American College of Rheumatology (ACR) Convergence 2024. The event will be held from November 14-19, 2024, in Washington, DC.
The poster will present preclinical data and key elements of the clinical trial design that supported the investigational new drug (IND) clearance for evaluating CB-010 in the GALLOP Phase 1 clinical trial. This trial focuses on patients with lupus nephritis (LN) and extrarenal lupus (ERL).
The presentation, titled 'Preclinical Analysis of CB-010, an Allogeneic anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE),' will be delivered by Elizabeth Garner, PhD, on November 16, 2024.
Caribou Biosciences (Nasdaq: CRBU) announced that the FDA granted Fast Track designations to two of its therapies: CB-010 for refractory systemic lupus erythematosus (SLE) and CB-012 for relapsed or refractory acute myeloid leukemia (r/r AML). CB-010, an allogeneic anti-CD19 CAR-T cell therapy, will be evaluated in the GALLOP Phase 1 clinical trial for lupus nephritis and extrarenal lupus, set to begin by year-end 2024. CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy, is currently being evaluated in the ongoing AMpLify Phase 1 clinical trial for r/r AML. These designations highlight the significant unmet medical needs and the potential of Caribou's off-the-shelf CAR-T cell therapies.
Caribou Biosciences (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in upcoming investor conferences. The company will attend the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 4, 2024, and the 2024 Wells Fargo Healthcare Conference in Boston, MA on September 5, 2024.
During these events, Caribou's leadership team will engage in one-on-one meetings with registered investors. This presents an opportunity for the company to showcase its progress and discuss its innovative CRISPR genome-editing technology with potential investors. For those interested in more details about Caribou's participation, additional information can be found on the Events page of the company's website.
Caribou Biosciences (CRBU) has appointed Dr. Tina Albertson as its new Chief Medical Officer. With 15 years of experience in clinical drug development of cellular therapies and biologics, Dr. Albertson will lead the company's clinical, regulatory, and medical affairs functions. She will oversee four clinical programs focusing on hematologic malignancies and autoimmune diseases.
Dr. Albertson's background includes roles at Lyell Immunopharma, where she initiated two Phase 1 trials for CAR-T cell and TIL therapies, and at Juno Therapeutics, where she led the development of BREYANZI, an FDA-approved therapy for large B cell lymphoma. Her expertise in strategic clinical development of CAR-T cell therapies is expected to be valuable as Caribou advances its allogeneic CAR-T cell therapies.
Caribou Biosciences (Nasdaq: CRBU) reported Q2 2024 financial results and provided a business update. The company is advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases, with data reports planned for 2024 and H1 2025. Key highlights include:
- Enrolling 2L LBCL and prior CD19 relapsed LBCL patients in the CB-010 ANTLER Phase 1 trial
- $311.8 million in cash, cash equivalents, and marketable securities, expected to fund operations into H2 2026
- Presented promising CB-010 clinical data at ASCO 2024, showing potential to rival autologous CAR-T therapies
- Advancing CB-011 for multiple myeloma and CB-012 for acute myeloid leukemia
- Planning to initiate CB-010 GALLOP Phase 1 trial for lupus by year-end 2024
Financial results show $3.5 million in licensing and collaboration revenue, $35.5 million in R&D expenses, and a net loss of $37.7 million for Q2 2024.
Caribou Biosciences (Nasdaq: CRBU) has appointed Dr. Terri Laufer to its scientific advisory board. Dr. Laufer is an immunologist and rheumatologist with over 35 years of experience in autoimmune disease research. She is an emeritus associate professor at the Perelman School of Medicine and practices at Penn Presbyterian Medical Center and Philadelphia VA Medical Center. Her expertise will support Caribou's GALLOP clinical program, which evaluates CB-010 for lupus. Dr. Laufer's research focuses on T cell development and MHC/HLA class II-positive antigen-presenting cells. She holds degrees from Princeton and Columbia University and completed postdoctoral research at Harvard.
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety and efficacy. The trial results indicated a median progression-free survival (PFS) of 14.4 months in patients with ≥4 HLA matches, compared to 2.8 months for those with ≤3 matches. CB-010 was well tolerated with no Grade 3 or higher cytokine release syndrome or graft-versus-host disease observed. Caribou plans to enroll ~20 additional patients to confirm these findings, with initial data expected in H1 2025. A pivotal Phase 3 trial is anticipated to start in H2 2025, pending confirmation of improved outcomes.
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing company, announced its upcoming participation in key events. On June 2, 2024, the company will host a webcast at 7:00 pm CDT, discussing CB-010 ANTLER Phase 1 trial data in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) from the 2024 ASCO Annual Meeting. The presentation will include insights from notable figures in hematology and oncology. Additionally, Caribou will present at the Jefferies Global Healthcare Conference on June 5, 2024, and participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024. Webcasts for these events will be available on the Caribou website for 30 days.